Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 1.00 |
| ▸ | PARP1 | P09874 | 3/20 | 0.76 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | GABRP | O00591 | 1/20 | 0.57 |
| ▸ | GABRD | O14764 | 1/20 | 0.57 |
| ▸ | PDE5A | O76074 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30522267 | 1.00 | KIF11 (1.00) | KIF11PARP1FTOALDH1A1KDM4E | |
| SCHEMBL14376207 | 0.92 | KIF11 (0.86) | KIF11PARP1FTOALDH1A1KDM4E | |
| SCHEMBL30571577 | 0.92 | KIF11 (0.86) | KIF11PARP1FTOALDH1A1KDM4E | |
| SCHEMBL29708168 | 0.92 | KIF11 (0.84) | KIF11PARP1ALDH1A1KDM4EMEN1 | |
| SCHEMBL4725998 | 0.92 | KIF11 (0.84) | KIF11PARP1ALDH1A1KDM4EMEN1 | |
| SCHEMBL71508 | 0.90 | KIF11 (0.82) | KIF11PARP1FTOALDH1A1KDM4E | |
| SCHEMBL25293367 | 0.86 | PARP1 (1.00) | KIF11PARP1FTOALDH1A1KDM4E | |
| Carbazole SCHEMBL29280510 | 0.85 | KIF11 (0.73) | KIF11PARP1FTOALDH1A1KDM4E | |
| SCHEMBL11235661 | 0.84 | KIF11 (0.73) | KIF11PARP1FTOALDH1A1KDM4E | |
| SCHEMBL6009589 | 0.84 | KIF11 (0.72) | KIF11PARP1ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105008352-B | Carbazole compounds useful as bromodomain inhibitors | 百时美施贵宝公司 | 2018-12-07 | — | — | CN | disclosed |
| CN-105008352-A | Carbazole compounds useful as bromodomain inhibitors | BRISTOL MYERS SQUIBB CO | 2015-10-28 | — | — | CN | disclosed |
| US-8076348-B2 | Acylguanidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-8076348-B2 | Acylguanidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-8076348-B2 | Acylguanidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-1923387-B1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| CN-101627013-A | Acylguanidine derivative | ASTELLAS PHARMA INC | 2010-01-13 | — | — | CN | disclosed |
| EP-2119704-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119704-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
| CN-101243046-A | Acylguanidine derivatives or salts thereof | ASTELLAS PHARMA INC (JP) | 2008-08-13 | — | — | CN | disclosed |
| EP-1923387-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| US-20060183022-A1 | Electrochemical cell | NEC TOKIN CORORATION (JP) | 2006-08-17 | — | — | US | disclosed |
| EP-1345898-A2 | TERACYCLIC CARBAZOLE DERIVATES AND THEIR USE AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050034-A2 | TETRACYCLIC CARBAZOLE DERIVATES AND THEIR USE AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| CN-1088209-A | Heterogeneous ring compound | WELLCOME FOUND (GB) | 1994-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | HTR5A, GRM5, HTR1E | KIF11 3092/4885PARP1 1520/4885FTO 933/4885 |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | HTR2B, HTR7, HTR3B | KIF11 4302/4885PARP1 2550/4885FTO 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.